Please assess the completion status of the following clinical trial:

Trial Title: Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05529)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A subject must be 12 years of age or older, of either sex, and of any race.~* A subject must have at least a 2-year history of SAR which exacerbates during the study season.~* A subject must have a positive skin prick test response to an appropriate seasonal allergen at Visit 1.~* A subject must be clinically symptomatic at the Screening and Baseline Visits.~Exclusion Criteria:~* A subject with a history of severe local reaction(s) or anaphylaxis to skin testing.~* A subject who has had an upper respiratory tract or sinus infection that required antibiotic therapy without at least a 14-day washout prior to the Screening Visit, or who has had a viral upper respiratory infection within 7 days prior to the Screening Visit.~* A subject who has used any drug in an investigational protocol in the 30 days prior to the Screening Visit.~* A subject who is participating in any other clinical study.~* A subject who is part of the staff personnel directly involved with this study.~* A subject who is a family member (parent, spouse, or sibling) of the investigational study staff.~* A female subject who is breast-feeding, pregnant, or intends to become pregnant.~* A subject previously randomized into this study.~* A subject who has a family member (parent, spouse, or sibling) currently enrolled in this study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Mometasone furoate nasal spray 200 mcg QD (once per day)
- Arm 2 (Type: PLACEBO_COMPARATOR): Matching placebo nasal spray

Based on this trial design, predict the completion outcome and termination type (if applicable).